These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10769990)

  • 1. Nafamostat mesilate modulates the release of platelet-activating factor during left ventricular assistance with hemofiltration in canine heart failure.
    Munakata M; Ono Y; Koyama M; Fukui K; Satoh K; Suzuki S
    Jpn J Thorac Cardiovasc Surg; 2000 Feb; 48(2):106-11. PubMed ID: 10769990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock.
    Doucet JJ; Hoyt DB; Coimbra R; Schmid-Schönbein GW; Junger WG; Paul L W; Loomis WH; Hugli TE
    J Trauma; 2004 Mar; 56(3):501-10; discussion 510-1. PubMed ID: 15128119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nafamostat mesilate, a synthetic protease inhibitor, attenuated hypercoagulability in a canine model of hemorrhagic shock.
    Koido Y; Kato K; Shimizu-Suganuma M; Shichinohe K
    Nihon Ika Daigaku Zasshi; 1997 Feb; 64(1):9-15. PubMed ID: 9119959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined administration of protease inhibitor and thromboxane A2 synthetase inhibitor for anticoagulation of a left ventricular assist device.
    Takahama T; Kanai F; Hiraishi M; Onishi K; Yamazaki Z; Naruse Y; Furuse A; Yoshitake T
    ASAIO Trans; 1990; 36(3):M141-4. PubMed ID: 2252644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175).
    Lukaszyk A; Bodzenta-Lukaszyk A; Gabryelewicz A; Bielawiec M
    Thromb Res; 1992 Jan; 65(2):229-39. PubMed ID: 1579898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tissue factor-factor VIIa by nafamostat mesilate; a reply to the rebuttal.
    Uchiba M; Okajima K; Murakami K; Okabe H; Takatsuki K
    Thromb Res; 1995 Feb; 77(4):381-2. PubMed ID: 7740530
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
    Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does nafamostat mesilate inhibit the tissue factor pathway?
    Matsuo T; Kario K; Matsuo M
    Thromb Res; 1994 Sep; 75(6):673-4. PubMed ID: 7831687
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect and pharmacokinetics of nafamostat mesilate adjunct to cold nondepolarizing cardioplegia in a canine model of cardiac preservation.
    Sunamori M; Yoshida T; Miyamoto H; Wang Y; Suzuki A
    Transpl Int; 1996; 9(4):364-9. PubMed ID: 8819271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nafamostat mesilate on the prevention of cerulein-induced acute pancreatitis.
    Lee JK; Ryu JK; Park JK; Lee SH; Yoon WJ; Kim YT; Jung HC; Yoon YB
    Pancreas; 2008 Apr; 36(3):255-60. PubMed ID: 18362838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of nafamostat mesilate on serum activities of pancreatic enzymes and plasma hormone levels].
    Wakayama S; Suzuki T; Sakai T; Matsuki A
    Masui; 1990 Jun; 39(6):734-40. PubMed ID: 2388392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition.
    Fujiwara Y; Furukawa K; Haruki K; Shimada Y; Iida T; Shiba H; Uwagawa T; Ohashi T; Yanaga K
    J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):731-9. PubMed ID: 21484229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional mechanisms of nafamostat mesilate-associated hyperkalaemia.
    Ookawara S; Tabei K; Sakurai T; Sakairi Y; Furuya H; Asano Y
    Eur J Clin Pharmacol; 1996; 51(2):149-51. PubMed ID: 8911880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ideal anticoagulation for use with a left ventricular assist device.
    Takahama T; Kanai F; Onishi K; Yamazaki Z; Furuse A; Yoshitake T
    ASAIO J; 1995; 41(3):M779-82. PubMed ID: 8573913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nafamostat enhances IBMX and secretin-stimulated water and bicarbonate secretion in the isolated, blood-perfused dog pancreas.
    Horiuchi A; Iwatsuki K; Chiba S
    Clin Exp Pharmacol Physiol; 1995 Dec; 22(12):987-9. PubMed ID: 8846521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation during use of a left ventricular assist device.
    Takahama T; Kanai F; Onishi K
    ASAIO J; 2000; 46(3):354-7. PubMed ID: 10826751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1.
    Hryszko T; Inaba K; Ihara H; Suzuki Y; Mogami H; Urano T
    J Trauma; 2006 Apr; 60(4):859-64. PubMed ID: 16612309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?
    Park KT; Kang DH; Choi CW; Cho M; Park SB; Kim HW; Kim DU; Chung CW; Yoon KT
    Pancreas; 2011 Nov; 40(8):1215-9. PubMed ID: 21775918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effect of therapeutic infusion of nafamostat mesilate (FUT-175) on hemodynamics in experimental acute pancreatitis.
    Dobosz M; Sledzinski Z; Juszkiewicz P; Babicki A; Stanek A; Wajda Z; Basinski A
    Hepatogastroenterology; 1991 Apr; 38(2):139-42. PubMed ID: 1855771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Removal of platelet-activating factor in experimental continuous arteriovenous hemofiltration.
    Ronco C; Tetta C; Lupi A; Galloni E; Bettini MC; Sereni L; Mariano F; DeMartino A; Montrucchio G; Camussi G
    Crit Care Med; 1995 Jan; 23(1):99-107. PubMed ID: 8001395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.